The Glow-Up, Per the Literature: Skin & Aesthetics Research Peptides

The short version

Peptides are short chains of amino acids — the same building blocks that make up proteins, only far smaller. Three of them keep turning up together under the heading of skin and aesthetics, and those three are what this desk covers: GLOW, a mixed vial containing three separate research peptides; GHK-Cu, a copper-carrying peptide found in serums and in a surprisingly deep research literature; and Melanotan II, a lab-designed molecule that switches on the skin's own pigment machinery without any sunlight.

The honest headline is that the three are nowhere near equally studied. GHK-Cu has small controlled human trials behind its skin and hair claims ^[4][8][10]. The GLOW blend has none as a blend — every claim made for it is borrowed from research on its individual parts ^[1]. Melanotan II has a handful of tiny early-phase studies and a much longer published list of things that went wrong ^[12][14][16].

Everything below traces to a listed source. Nothing here is a product, a protocol, or a prescription.

What "the glow-up, per the literature" actually means

Search results are full of glow-up peptide protocols. Peer-reviewed journals hold something narrower and far more useful: measurements. Keeping the two apart is the entire job of this site.

The cosmetic outcomes people care about — firmer skin, softer lines, an even tone, denser hair, a change in colour — each map onto a different quantity of published evidence, and the quantities are wildly uneven. Firmness and fine lines under a topical copper peptide have small controlled human studies behind them, including a review reporting procollagen synthesis increased in 70% of GHK-Cu-treated subjects against 50% for vitamin C and 40% for retinoic acid ^[8]. Hair count has one 45-man randomized trial, and of a combination formulation rather than the peptide alone ^[10]. Skin darkening under a melanocortin agonist has a well-described mechanism and a long trail of published case reports about what else that mechanism does ^[12][14]. A three-peptide blend sold for skin repair has, as a blend, nothing at all ^[1].

So the frame is simple, and it repeats on every page: name the outcome, name the strongest study that speaks to it, then say plainly where that study stops. Enthusiasm is welcome on this desk. It just has to arrive with a citation and a caveat attached.

What research peptides are — and what "research use only" really means

Peptides sit between single amino acids and full proteins: long enough to fold into a shape a receptor recognises, short enough to be made synthetically at scale. The three compounds here reach the skin by three different routes — one as a copper complex applied to the surface or reconstituted for injection, one as a mixed injectable vial, one as an injected melanocortin analog.

Regulatory status is not uniform across them, and the differences matter more than the marketing suggests:

• Topical Copper Tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient in the US, EU and UK, with a long consumer safety record. Injectable or otherwise systemic GHK-Cu is a different proposition: unapproved, research-only, and without validated human pharmacokinetic data.
• BPC-157 and TB-500, two of the three peptides in the GLOW vial, are unapproved research chemicals. In 2023 the FDA placed BPC-157 in a category of bulk drug substances identified as not eligible for pharmacy compounding pending further evaluation, and both peptides are prohibited in sport at all times under World Anti-Doping Agency rules.
• Melanotan II has no approved human indication anywhere. Regulators including the FDA, Australia's TGA, the UK's MHRA and Ireland's HPRA have issued warnings about melanotan products, and it falls under the anti-doping catch-all category for non-approved substances.

"Research use only" is a supply-chain label, not a safety finding. It describes how a vial may lawfully be sold, and says nothing whatever about whether the contents are pure, correctly labelled, or safe.

The evidence ladder, shortest rung first

Reading these three in order of how much controlled human data stands behind them produces a useful — and slightly deflating — ladder.

GHK-Cu sits highest, and even it is modest: small topical dermatology studies, one 45-patient randomized hair trial of a combination product ^[10], a quantified skin-penetration study ^[11], and a very large mechanistic and gene-expression literature concentrated in a single research group ^[9]. Real evidence, narrow in scope.

Melanotan II has controlled human data of a peculiar kind: a double-blind crossover study in 10 men, of erectile response rather than anything cosmetic ^[16]. Its pigment mechanism is well characterised, but no Phase II or Phase III trial was ever completed, and its most recent literature is dominated by case reports — reversible oral-mucosal pigmentation ^[12], renal infarction ^[14], and more.

GLOW sits lowest, not because its ingredients are unstudied but because the vial is not what was studied. A 2026 review naming all three constituents concluded that unapproved peptides of this class show favourable tissue-repair outcomes in animal models while rigorous human safety data remain scarce, with real potential for harm ^[1]. Worth comparing side by side before reading any single page as good news.